Experts around the world are working together to find viable treatments and vaccines for the novel coronavirus. While Moderna biotech company is entering its final phase of testing with the vaccine, there are also some great treatments in the works.
It’s also worth noting the fact that CNN just reported that the FDA could be issuing an emergency use authorization for the vaccine. This could be happening in a matter of weeks after a vaccine meets all the necessary requirements.
Now, according to the latest reports coming from Reuters, Eli Lilly and Co (LLY.N) said this Thursday that it had started mid-stage testing of one of its experimental treatments for COVID-19.
It’s been also revealed that the drugmaker reported second-quarter sales that missed estimates due to the pandemic.
Lilly is working on two antibody treatments
The firm has been working on two antibody treatments, LY-CoV555 in partnership with the Canadian biotech AbCellera, and another one is being developed with Chinese drugmaker Shanghai Junshi Biosciences Co Ltd (1877.HK), Reuters said.
It’s also worth noting that Lilly told the news agency back in June that it could have a drug used to treat COVID-19 and authorized for use as early as September if either of the two antibodies will be proving to be successful in trials.
“The company said on Thursday LY-CoV555 had moved to mid-stage trials, while the other treatment had demonstrated safety and tolerability to move into further stages of development,” Reuters notes.
We recommend that you check out more details about the issue on Reuters’ official post on the website.
Other treatments are in the works
There are various other treatments in the works these days.
Not too long ago, we addressed the fact that steroid treatments for the coronavirus have been a topic among experts lately.
It’s been just revealed that a simple blood test could have the ability to find which coronavirus patients can be helped by steroid treatments and which ones could be harmed by such solutions.